MetaVia Inc.
MetaVia is a clinical-stage biotechnology company focused primarily on developing pharmaceuticals for cardiometabolic diseases. Its two main programs target MASH and obesity. Vanoglipel (DA-1241), an oral GPR119 agonist, is being developed for MASH and Type 2 Diabetes Mellitus, as a standalone or combination therapy. DA-1726 is a peptide GLP-1 and glucagon receptor dual agonist being studied for obesity and designed for once-weekly subcutaneous administration. Both candidates are in clinical trials. MetaVia also has four legacy programs: ANA001 for moderate COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for cognitive impairment, and gemcabene for dyslipidemia. The company is not planning to advance these programs and has entered an exclusive out-license agreement for NB-01. Its operations principally involve research and development, preclinical development, clinical trials, and raising capital. MetaVia is headquartered in Cambridge, Massachusetts.
No SEC Form 4 filings for $MTVA in the last 30 days.
See all $MTVA insider activity →MetaVia Inc. (MTVA) reported interim Phase 1 data for DA-1726, showing a 68% placebo-adjusted reduction in liver fat and 13.5% weight loss. The trial also demonstrated improved HbA1c levels. Full data is expected in Q1 2027, with a Phase 2 study planned for 2027.
MetaVia Inc. (MTVA) will present Phase 1 clinical trial data for DA-1726, a novel dual oxyntomodulin analog, at the Precision Liver Symposium 2026. The presentation, titled 'DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial,' will highlight the drug's potential for weight loss and metabolic benefits.
MetaVia Inc. (MTVA) appointed Sarah Browne as Chief Medical Officer, effective October 12, 2026. Browne has over 20 years of experience in clinical development and regulatory science. Her hire precedes the expected Q4 2026 topline results from Phase 1 Part 3 of DA-1726, a drug targeting cardiometabolic diseases and MASH.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MTVA (MetaVia Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MTVA coverage spans financial news, technology and earnings.
Positive Phase 1 data is likely to lift investor sentiment and drive short‑term buying pressure.
Positive clinical‑trial news likely lifts sentiment and creates buying interest ahead of the symposium.
The new CMO brings extensive experience in cardiometabolic drug development, which could de‑risk the DA‑1726 program and support upcoming trial readouts.
DA-1726 dose-titration completion and upcoming 16-week topline are near-term execution milestones that can shift probability-weighted outcomes and funding expectations.
Dilution via equity plan share increase and potential liquidity/valuation reset from an approved reverse split are the key near-term trading overhangs.
AlphAI scores every news story that mentions MTVA with an AI model for sentiment and relevance, and aggregates insider trades from MetaVia Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MetaVia Inc. (MTVA) reported interim Phase 1 data for DA-1726, showing a 68% placebo-adjusted reduction in liver fat and 13.5% weight loss. The trial also demonstrated improved HbA1c levels. Full data is expected in Q1 2027, with a Phase 2 study planned for 2027.
MetaVia Inc. (MTVA) will present Phase 1 clinical trial data for DA-1726, a novel dual oxyntomodulin analog, at the Precision Liver Symposium 2026. The presentation, titled 'DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial,' will highlight the drug's potential for weight loss and metabolic benefits.
MetaVia Inc. (MTVA) appointed Sarah Browne as Chief Medical Officer, effective October 12, 2026. Browne has over 20 years of experience in clinical development and regulatory science. Her hire precedes the expected Q4 2026 topline results from Phase 1 Part 3 of DA-1726, a drug targeting cardiometabolic diseases and MASH.
MetaVia Inc. (MTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fou
MetaVia Inc. (MTVA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001638287 0001638287 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
